ArticleAsthma research and practice2015
Allergic rhinitis: the "Ghost Diagnosis" in patients with asthma.
Article in Asthma research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.Respiratory research · 2021Pooled it
- Pharmacist-Led Education Intervention for Adults With Allergic Rhinitis: A Randomized Clinical Trial.JAMA network open · 2025Trial
- An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu in Asian Patients with Allergic Rhinitis.Drugs - real world outcomes · 2026Article
- Connecting the Airways: Current Trends in United Airway Diseases.Journal of personalized medicine · 2026Review
- Atopic diseases in pediatric population: prematurity and small for gestational age.BMC pediatrics · 2025Article
- Efficacy and Safety ofAdvances in respiratory medicine · 2025Review
- Expert Panel Consensus Recommendations for Allergic Rhinitis in Patients with Asthma in India.Pulmonary therapy · 2025Article
- Ayurveda Management of Allergic Rhinitis: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2024Article
- Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet.Pharmaceutics · 2024Article
- Article
- Comparison of circulating fibrocytes from non-asthmatic patients with seasonal allergic rhinitis between in and out of pollen season samples.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Microbiome First Medicine in Health and Safety.Biomedicines · 2021Review
- Integration of in vitro allergy test results and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA).Clinical and translational allergy · 2021Review
- Identification of key genes in allergic rhinitis by bioinformatics analysis.The Journal of international medical research · 2021Article
- Prevalence and risk factors associated with allergic rhinitis in Mexican school children: Global Asthma Network Phase I.The World Allergy Organization journal · 2021Article
- Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.The World Allergy Organization journal · 2020Article
- Anti-Inflammatory Effects of aMolecules (Basel, Switzerland) · 2020Article
- Impact of comorbid conditions on asthmatic adults and children.NPJ primary care respiratory medicine · 2020Review
- The Role of New IL-1 Family Members (IL-36 and IL-38) in Atopic Dermatitis, Allergic Asthma, and Allergic Rhinitis.Current allergy and asthma reports · 2020Review
- Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma.Frontiers in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Allergic rhinitis (AR) is a common comorbidity of asthma that contributes to asthma severity. Although over 80 % of asthmatics have AR, the condition is frequently underdiagnosed in subjects with asthma. AR itself is also a highly prevalent condition, affecting 10-30 % of adults and up to 40 % of children. AR has been associated with both increased risk of asthma development and asthma severity. The exact mechanisms underlying these relationships have yet to be fully elucidated, but evidence supports a role for allergen sensitization. Compared to those with asthma alone, patients with comorbid AR and asthma have greater use of health care resources, including visits to the general practitioner, emergency department and hospitalizations. Pharmacological treatment of AR reduces this health care burden. Immunotherapy for AR improves both asthma and rhinitis symptoms in addition to preventing future allergen sensitizations and asthma development. Appropriate recognition, diagnosis and treatment of AR can significantly reduce asthma morbidity and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.